FOLFIRINOX Induction Chemotherapy for Synchronous Liver Metastases
Multicenter Cohort Study of Mid/Lower Rectal Cancer With Resectable Synchronous Liver Metastases Treated With FOLFIRINOX Induction Chemotherapy
Assistance Publique - Hôpitaux de Paris
550 participants
May 1, 2026
OBSERVATIONAL
Conditions
Summary
SYNCHRONOX is a multicenter cohort (retrospective then prospective) intending to include 550 patients with mid or low rectal adenocarcinoma (pMMR, T3-T4 and/or N+) and resectable synchronous liver metastases, treated upfront with at least two cycles of induction FOLFIRINOX chemotherapy. The primary objective is to determine, at 18 months, the R0 resection rate of both tumor sites (rectum and liver), while secondary objectives focus on 3 year overall and progression free survival, radiological and pathological responses, postoperative morbidity and mortality, and comparison of the different surgical strategies after FOLFIRINOX.
Eligibility
Inclusion Criteria3
- Adult subjects aged 18 years and older
- Adenocarcinoma of the middle and/or lower rectum pMMR T3, T4, and/or N+
- Resectable synchronous liver metastases
Exclusion Criteria3
- Minor under the age of 18.
- Presence of extrahepatic metastases
- Induction chemotherapy with FOLFIRINOX of less than 2 courses
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07467434